

| Drug   | Schedule |
|--|----------|
| Amobarbital (2125) .....                               | II       |
| Pentobarbital (2270) .....                             | II       |
| Secobarbital (2315) .....                              | II       |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333) ..... | II       |
| Phenylacetone (8501) .....                             | II       |
| Cocaine (9041) .....                                   | II       |
| Codeine (9050) .....                                   | II       |
| Dihydrocodeine (9120) .....                            | II       |
| Oxycodone (9143) .....                                 | II       |
| Hydromorphone (9150) .....                             | II       |
| Diphenoxylate (9170) .....                             | II       |
| Ecgonine (9180) .....                                  | II       |
| Hydrocodone (9193) .....                               | II       |
| Meperidine (9230) .....                                | II       |
| Methadone (9250) .....                                 | II       |
| Morphine (9300) .....                                  | II       |
| Thebaine (9333) .....                                  | II       |
| Oxymorphone (9652) .....                               | II       |
| Alfentanil (9737) .....                                | II       |
| Remifentanil (9739) .....                              | II       |
| Sufentanil (9740) .....                                | II       |
| Fentanyl (9801) .....                                  | II       |

The company plans on manufacturing the listed controlled substances in bulk for sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cody Laboratories, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cody Laboratories, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013-03881 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration; Cedarburg Pharmaceuticals, Inc.**

By Notice dated November 5, 2012, and published in the **Federal Register**

on November 13, 2012, 77 FR 67676, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Drug   | Schedule |
|--|----------|
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333) ..... | II       |
| Fentanyl (9801) .....                                  | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Regarding the drug code (8333), the company plans to use this controlled substance to manufacture another controlled substance.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cedarburg Pharmaceuticals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013-03885 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration; INB Hauser Pharmaceutical Services, Inc.**

By Notice dated November 1, 2012, and published in the **Federal Register** on November 9, 2012, 77 FR 67398, InB Hauser Pharmaceutical Services, Inc., 6880 N. Broadway, Suite H, Denver, Colorado 80221, made application by letter to the Drug Enforcement

Administration (DEA) to be registered as a bulk manufacturer of 4-Anilino-N-phenethyl-4-piperidine (8333), a basic class of controlled substance listed in schedule II.

The company plans to manufacture the listed controlled substance in bulk for distribution and sale to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of InB Hauser Pharmaceutical Services, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated InB Hauser Pharmaceutical Services, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems; verification of the company's compliance with state and local laws; and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: February 8, 2013.

**Joseph T. Rannazzisi,**  
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2013-03886 Filed 2-20-13; 8:45 am]

**BILLING CODE 4410-09-P**

**NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES**

**Proposed Collection of Information; Comment Request**

**AGENCY:** National Endowment for the Arts, National Foundation on the Arts and the Humanities.

**ACTION:** Notice. Proposed collection; comment request.

**SUMMARY:** The National Endowment for the Arts (NEA), as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial